{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-041344","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.889648+00:00","generated_at":"2026-05-31T03:58:56.812020+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant's Dermavant to be acquired by Organon for $1.2B","bullets":["Organon (OGN) will acquire Dermavant, a Roivant (ROIV) subsidiary, for $1.2B in cash and milestone payments.","Deal includes VTAMA cream (tapinarof) 1%, approved for plaque psoriasis in adults (May 2022).","sNDA for atopic dermatitis under FDA review; PDUFA decision expected Q4 2024.","VTAMA is a once-daily steroid-free topical with no safety label warnings or duration/BSA restrictions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-041344","json":"https://secwatch.observer/filing/0001140361-24-041344.json","markdown":"https://secwatch.observer/filing/0001140361-24-041344.md","text":"https://secwatch.observer/filing/0001140361-24-041344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041344/0001140361-24-041344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041344/ef20036017_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:58:56.812020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}